who is eligible for glp-1 Indications GLP-1/GIP RA Summary Sheet and Beyond! Did you know we offer

GEP44 mediates insulin-independent glucose uptake in muscle via interactions with Y1-R GEP44 may also reduce serum glucose levels via direct interactions resulting in increased glucose uptake in muscle tissue

VERTIS CV Patients with atherosclerotic cardiovascular disease and T2DM were randomized to ertugliflozin 5mg (n=2752), 15mg (2747), or placebo (n=2747) and the primary composite outcome of cardiovascular death and non-fatal MI or stroke was determined after a mean duration of follow-up of 3.5 years (160)

Studies have shown that these medications can offer other health benefits in some people with and without diabetes, such as lowering cardiovascular risks and treating sleep apnea

Bradshaw HB, Walker JM

Prescriber Model & Clinical Quality The "telehealth" label still covers a wide range of medical standards in 2026

Thirdly , theres also a patent application (IN202047010224) (pdf) pending by Novo Nordisk, filed in 2020 with priority date of 24/08/2017, for a specific formulation of semaglutide (the active ingredient in its commercial blockbuster drug, Ozempic) described as Semaglutide liquid formulations (no more than 0.01% (w/w) phenol. Adding to the complexity is a recent revocation petition filed by DRL in May 2025 (as reported by the media here)